Ionis Statement About Results From An Analysis Of Exploratory Cardiac Endpoints In The Phase 3 NEURO-TTRansform Study Of Eplontersen
Portfolio Pulse from Charles Gross
Ionis Pharmaceuticals announced new results from a 66-week analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen, a treatment for hereditary transthyretin-mediated amyloid polyneuropathy. The results showed stabilization or improvement in cardiac function and structure. Ionis and AstraZeneca are seeking regulatory approval for eplontersen in the U.S. and globally. AstraZeneca has exclusive rights to commercialize eplontersen outside the US. The FDA granted a PDUFA action date of Dec. 22, 2023.
October 07, 2023 | 7:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca has exclusive rights to commercialize Ionis' eplontersen outside the US, potentially expanding its product portfolio and market reach.
Having exclusive rights to commercialize a promising drug like eplontersen can potentially expand AstraZeneca's product portfolio and market reach, leading to potential revenue growth and stock price appreciation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ionis' eplontersen shows promising results in Phase 3 study, potentially boosting the company's portfolio and future revenues.
Positive clinical trial results often lead to increased investor confidence and potential stock price appreciation. The news of seeking regulatory approval also indicates progress in the drug's development, which could lead to future revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100